Best Value Stocks to Buy for September 16th

Zacks highlighted Par Pacific Holdings, Kennametal and Tenet Healthcare as Rank #1 (Strong Buy) value stocks. Current-year consensus EPS estimates increased 19.5% for Par Pacific, 54.1% for Kennametal and 20.2% for Tenet over the past 60 days. The article is analyst-driven stock-selection commentary rather than a company-reported operational or financial update.

Analysis

This is low-information promotional research rather than a fundamental catalyst; estimate revisions are useful only if they reflect changes in end-market conditions or company-specific execution that have not already been priced. Do not treat the cited revision magnitude as independently validated. The near-term tradable signal is therefore limited to monitoring whether sell-side revisions broaden across each peer group and whether management confirms the drivers in the next earnings cycle.

PARR has the clearest operating leverage but also the highest commodity and regional refining sensitivity: sustained West Coast/Hawaii product cracks and reliable refinery utilization would matter far more than consensus changes. A deterioration in gasoline/distillate cracks or unplanned downtime can erase apparent value quickly; use VLO and MPC as liquid refining-beta comparables rather than extrapolating a single-name estimate move. Over 6-18 months, renewable-fuels capex, regulation, and island-market supply discipline will determine whether its discount persists.

KMT is a more useful cyclical read-through than a standalone momentum signal. If revisions coincide with improving industrial production, aerospace build rates, and mining activity, the benefit extends to machining peers such as MRCY? No: better comparables are OSK and industrial distributors, while stronger cutting-tool demand would favor KMT versus broad industrial ETFs only if volume—not merely pricing or cost cuts—drives margin expansion. THC's key issue is whether earnings strength converts to durable free cash flow after labor inflation, reimbursement mix, and leverage; hospital peers HCA and UHS offer cleaner relative-value benchmarks.

Contrarian view: value-screen visibility often attracts transient retail flows but rarely changes institutional ownership without a guidance raise, accelerated buyback, or deleveraging event. QBTS appears only through unrelated promotional material and has no evidentiary connection to the three operating businesses; avoid inferring a quantum-computing signal from this item.

Key Decisions for Investors

• No immediate directional trade solely on this article; require the next earnings release or a company guidance revision to validate that estimate changes are fundamental rather than model-driven.
• Watch PARR for a 1-3 month tactical long only if regional refining margins remain firm and utilization is maintained; hedge broad refining-beta risk with a short VLO or MPC basket. Exit on a material crack-spread reversal or disclosed operational downtime.
• Monitor KMT versus XLI over the next 1-2 quarters: initiate long KMT / short XLI only if organic order growth and volume-led gross-margin expansion are confirmed. Falsify on sequential order decline or guidance that attributes improvement primarily to cost actions.
• For healthcare exposure, prefer a relative-value screen of THC versus HCA and UHS after quarterly results. Go long THC only if free-cash-flow conversion and net leverage improve; a reimbursement shortfall, renewed labor-cost pressure, or leverage stagnation invalidates the thesis.